CASE/0257/08/24 - Complainant v GSK

Alleged unlicensed promotion of Trelegy Ellipta in a COPD medicines optimisation toolkit

  • Case number
    CASE/0257/08/24
  • Complaint received
    04 August 2024
  • Completed
    24 June 2025
  • Appeal hearing
    No appeal
  • Applicable Code year
    2021
  • No breach Clause(s)
  • Additional sanctions

Case Summary

This case was in relation to a GSK COPD (chronic obstructive pulmonary disease) medicines optimisation toolkit. The complainant alleged that it promoted Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol) for an unlicensed indication because the licence was specific to moving from dual inhaler use to triple therapy, and did not cover moving patients from multiple inhaler triple therapy to single inhaler triple therapy.

The outcome under the 2021 Code was:

No Breach of Clause 2

Requirement that activities or materials must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 5.1

Requirement to maintain high standards at all times

No Breach of Clause 11.2 (x2)

Requirement that a medicine must be promoted in accordance with the terms of its marketing authorisation and must not be inconsistent with the particulars listed in its summary of product characteristics

This summary is not intended to be read in isolation.
For full details, please see the full case report below.